Member Info for AquaeSulis01

They wont have "run out" of lysate. Runtime for producing lysate is estimated at just 18 hrs, and as Croda is a B2B Supplier, marketing to their VIP clients who account for most of their Business will have been direct to them and taken place some time ago, whilst it is more cost effective to market to the many potential smaller new Customers via the trade events.

https://lemminginvestor.substack.com/p/skinbiotherapeutics-plc-004

Toyin, think the confusion around the word Global is because it was launched at an event called "In-Cosmetics Global". The wording in the SBTX RNS announcing it was worded thus;

"Croda Launches Zenakine™ at in-cosmetics Global, Amsterdam

· The FIRST formal, public launch of SkinBiotix, now named Zenakine™, as Croda's newest active ingredient

· Launched at in-cosmetics Global, the world's largest cosmetic ingredients exhibition"

implying the first of many launches at different events around the world

My question submitted.

Harry, an announcement in Mar 24 read; “KEFI Gold and Copper (AIM: KEFI), the gold and copper exploration and development company with projects in the Federal Democratic Republic of Ethiopia and the Kingdom of Saudi Arabia, is pleased to announce a fundraising package to facilitate full project launch at Tulu Kapi, with project launch expected to occur in mid-2024.”

A further fundraise in Dec 24 read “KEFI Gold and Copper (AIM: KEFI), the gold and copper exploration and development company with projects in the Federal Democratic Republic of Ethiopia and the Kingdom of Saudi Arabia, announces a Capital Raise (as defined below) to fund closing costs and final preparations for project launch at Tulu Kapi, with full project launch expected in early 2025.”

How on the back of the need to continually raise equity to keep the lights on because of missed deadlines do you justify your renumeration package increasing from £362K in 2023 to a staggering £733k in 2024?

I will be looking for reassurance at the EOY Results that the Revenue expectations excluding Croda have been met and that the royalties from forward sales to VIPs and net tier clients have contributed sufficiently for SBTX to be cash positive at which point happy to be patient as Zenakine as others have pointed out looks a winner.

Despite the current sp, I will not be purchasing a single extra share pre-results because SA has failed to deliver on his previous forecasts and I have concerns that the extra 23 staff acquired from BTS plus the additional 6 staff from Dermatonics will all have attracted the additional Nat Ins costs since the acquisitions were budgeted for and planned and hence may detract from EBITDA expectations.

Examples of recent SA announcements that have failed to materialise can be found at the 11th Oct 2024 Inv Meets Presentation:

AxisBiotix Ps Seeking NPF accreditation in USA prior to launch – Why hasn’t this happened yet?

AxisBiotix Acne advanced formulation in progress with an expectation to launch end 2024 – Why hasn’t this happened yet?

Discussions continue with 2 National high street retail chains – Why hasn’t this happened yet despite having staff ex Dermatonics with the contacts at Superdrug and Boots?

BTS have the ability to produce capsule version of AxisBiotix products – Progress?

Exactly Smellyben. No wonder we have had to have the regular placings with those sort of Board costs

Fair play for flagging up Robj. Harry Adams being paid £733k; salary and Fees £300k + £173k other compensation comprising fees paid in excess of the 220 days retention arrangement (four day week) , as well as medical insurance premiums + £185K bonus in shares + £75k bonus in cash for missing every deadline published. I hope at the AGM, if the Financing has still not been signed off a motion to sack this ineffective Board is proposed.

"No more dilution. No more fundraising from shareholders." You mean apart from the $5M share issues on financial sign-off I take it?

Great fan of the porridge mol but interesting to note the price has not changed for 4 years despite inflation

Think that there is a good chance of hitting the revenue target martinu in 2025 but not sure that will be sufficient to turn a profit as the focus on cost cutting has now seemingly been dropped to achieve the revenue targets via high marketing spend

Should add that at least the Focus is now aligned with the Strategic Objectives outlined in the Commercial Update which was strangely was not the case for 2024:

We are pleased to report good progress on all our main strategic objectives set out for 2024 which were:-

· increasing our number of partners and sales in our key target markets of the USA and Asia;

· investing in e-commerce channels to increase direct-to-consumer sales;

· growing our sales of final branded and white label products containing our ingredients to deliver a dual income stream.

Our focus for 2025 is to continue to build our business in USA, India, and Asia whilst investing in ecommerce activities in multiple territories including China, India, and Europe, and launch second generation products.

"a company's focus should absolutely be in line with its strategic objectives. A strategic objective is a measurable, high-level goal that outlines what an organization wants to achieve. A company's focus is the specific areas or activities that it concentrates its resources and attention on. When these two align, the company is more likely to achieve its goals and maximize its effectiveness.

Here's why alignment is crucial:

Efficiency and Effectiveness:

When a company's focus directly supports its strategic objectives, it can allocate resources and efforts more efficiently, leading to better outcomes.

Clarity and Direction:

Strategic objectives provide a clear direction for the organization, and a focused approach ensures that everyone is working towards the same goals.

Competitive Advantage:

By focusing on the right areas and implementing strategies effectively, a company can gain a competitive edge in the market.

Resource Optimization:

A well-aligned focus helps a company avoid wasting resources on activities that are not directly contributing to its strategic goals.

Employee Alignment:

When employees understand how their work aligns with the company's strategic objectives, it fosters a sense of purpose and commitment. "

Yes Bk2011 am looking forward to the outlook statement to see whether there is any additional updates from the Outlook in the March EOY Commercial Update RNS.

What it did prompt me to do was revisit the 2023 EOY Results to see what the focus was for 2024:

Post Period 2023 FY Results

"Our focus in 2023 is on looking forward with the aim of each business unit reaching profitability by the end of the year. We believe this can be achieved by a reduction in costs, a focus on existing partners returning to forecast, bringing in new partners particularly in the USA and Asia, and expanding e-commerce channels to reduce partner dependency. With our products winning awards in Europe, Asia, and the USA and an increasing number of large companies like The Hut Group, Holland and Barrett, Apollo Hospitals, and Nahdi Medical using our products, we believe we are in strong position for further growth.”

Results from the 2024 Commercial Update stated

Consumer Health and Ecommerce

Within e-commerce Amazon sales increased 156%, China 28%, and our own website by 5%. In terms of profitability, our own website was profitable every month and overall in 2024 due to its low marketing spend, China seven out of twelve months with a small overall loss, and Amazon was loss making every month due to the investment in marketing needed to grow the customer base.

North America

We believe our North America business has taken a significant step forward in 2024 and we expect it to be profitable in 2025 with existing customers and making a material contribution to overall profitability going forward.

Optibiotix Health India

We believe that our agreement with Morepen and the upcoming launch of more products under the Dr Morepen brand, plus other partner launches and the reorder of products by Apollo pharmacies could generate significant revenues and will bring profitability to this part of the business during 2025.

2024 Oulook

Our focus for 2025 is to continue to build our business in USA, India, and Asia whilst investing in ecommerce activities in multiple territories including China, India, and Europe, and launch second generation products.

Which I presume means not profitable until 2026, I just hope the loss is minimal this year with costs brought under tighter control

"Take recently the hype on Axisbiotix product at SBTX which they were ramping 25,000 units per week from launch" blimey, how recently was that letitrun?

Mol, let's focus on what we both agree on which is what really should be p* you off and that is "at least opti has £750,000 in the bank albeit i wasn't overly happy with the price paid" especially after the March commercial update that stated "This means we enter 2025 with a strong balance sheet (£9.1m; 2023:£9.4m), a strong cash position (£740k; 2023: £635k) no debt, a strong first quarter order book, a solid pipeline of existing customers reordering, and new customers looking to launch our award winning products in different applications around the world. Post period the Company sold 1,211,567 SBTX shares at an average price of 20p, generating gross proceeds of £257K."

Mol, you miss the point, they are not strategic investors, in fact if you care to calculate the number of shares issued from the £500K share of the total £750K declared in the RNS and then compare it with the number of shares declared against Alumni on the Opti Website it appears some shares have already been flipped

I take it people do understand what the PIPE Market involves?

"What Is a Private Investment in Public Equity (PIPE)?

Private investment in public equity (PIPE) is the buying of shares of publicly traded stock at a price below the current market value (CMV) per share. This buying method is a practice of investment firms, mutual funds, and other large, accredited investors. A traditional PIPE is one in which common or preferred stock is issued at a set price to the investor, while a structured PIPE issues common or preferred shares of convertible debt.

The purpose of a PIPE is for the issuer of the stock to raise capital for the public company. This financing technique is more efficient than secondary offerings because they offer fewer regulatory hurdles with the Securities and Exchange Commission (SEC). On the downside, PIPEs tend to be an expensive source of capital since the issuer must take a discount on the stocks sold."

https://www.investopedia.com/terms/p/pipe.asp

And that is the nature of the deal Opti has struck with their "strategic investor"

https://mcusercontent.com/396b8dd522c6ad8d3451a57f1/files/de4505d8-cf45-4cd2-6df8-d544f7d18ad6/Q_A_Alumni_Capital_Brings_New_Blood_to_PIPE_Market.pdf

Freedman, because of its illiquid state, Opti has yet to sell a single share in PBX although if the PBX Board are serious about making significant purchases of their own shares, one way to do it would be to purchase direct with Opti off- market. I am also a Customer of Opti products; the slimexpert porridge is delicious and a regular breakfast for me and a mid-morning indulgent bar with a coffee is also a regular pleasure. Not sure I would get the same satisfaction with a jab as food is one of the few pleasures as you get older. So I see a long term future for Opti products and I am convinced that bringing costs under control will quickly see the books balanced without the need to sell the assets. In the short term, success I suspect lies with the strength or otherwise of the Dr Morepen launch and like everyone else I wait to see the outlook statement in the EOY Results.

Researcher, I find your decision to sell Opti and recommend others to sell at the current sp and buy sbtx illogical. I too hold SBTX, but continue to hold my Opti shares firstly to retain an influence to resolve current governance issues, but also because if you believe SBTX shares are about to take off then Opti's 8% holding will also rocket in value from the current £3.5M; throw in the current market cap value of PBX, also expected to appreciate, at £4.4M and the residual Opti MC of £5.2M looks ridiculously cheap. Things need to improve here, but now is not the time to sell

It is not just about a growth in sales; no point increasing revenue if you are still selling at a loss because costs have not been brought under control. Worth reminding ourselves that March 24 so a fundraise of over a £1M also in addition so selling SBTX shares to :

"The net proceeds of the Fundraise will be utilised to invest in driving sales growth by:-

1. active account management of existing partners by co-investing in publicity, marketing, and promotions to increase sales;

2. increased presence of the Company's stands at major exhibitions to attract new partners, particularly in the USA and India to mitigate dependency on a small number of partners;

3. investing in marketing the Company's products to grow sales on e-commerce platforms in India, China, USA, Europe, and the Gulf States; and

4. launch its second generation SweetBiotix and MicroBiome Modulator products."

Well we might ask what happened to the money from that raise set aside for the sweetbiotix launch?

Does AIM rule 26 require a company to declare all shareholders with over % holdings whether the holders wishes it to be declared or not?

AIM Rule 26 requires companies listed on the AIM market to disclose certain information on their websites, including details about significant shareholders. Specifically, companies must provide the identity and percentage holdings of significant shareholders, which suggests that disclosure is mandatory regardless of whether the shareholder wishes to remain private.

So you believe the "US Investor" has held onto their shares then?